PBH Earnings Prediction
The chart below shows how PBH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PBH sees a -1.67% change in stock price 10 days leading up to the earnings, and a -1.91% change 10 days following the report. On the earnings day itself, the stock moves by +1.40%. This data can give you a slight idea of what to expect for the next quarter's release.
PBH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
283.79M
-0.88%
6.23%
Gross Margin
53.50%
-0.76%
1.85%
Operating Margin
29.72%
-3.57%
10.20%
Net Margin
19.16%
2.41%
4.30%
EPS
1.09
1.87%
11.22%
No Data Available
PBH Earnings Analysis
Prestige Consumer Healthcare Inc. Corporation (PBH.N) Earnings Conference Call
Positive
Free Cash Flow Growth: 1. Strong Free Cash Flow: Generated $68 million in free cash flow for Q2, reflecting double-digit growth compared to the prior year, supporting capital deployment for shareholder value enhancement.
Debt Reduction Strategy: 2. Debt Reduction: Reduced debt by $40 million in Q2, resulting in a leverage ratio decline to 2.7x, while continuing to repurchase shares opportunistically.
International Revenue Increase: 3. International Segment Growth: Achieved a 4.8% increase in International segment revenues for the first half of fiscal '25, driven by strong performance from the Hydralyte brand.
Consistent Gross Margin Performance: 4. Stable Gross Margin: Maintained a gross margin of 55.1% for the first half of fiscal '25, with expectations of approximately 56% for the full year, supported by pricing actions and cost savings.
Earnings Per Share Increase: 5. Earnings Per Share Growth: Reported EPS of $1.09 for Q2, a slight increase from the prior year, driven by effective capital allocation and improved interest expense.
Negative
Q2 Revenue Decline: Q2 revenue of $283.8 million declined 90 basis points from $286.3 million in the prior year, primarily due to Clear Eyes supply chain limitations and cough and cold ordering patterns.
Revenue Decline Overview: For the first 6 months of fiscal '25, revenues decreased 2.5% organically versus the prior year, with North America segment revenues decreasing 3.7%.
Gross Margin Decline: Total company gross margin of 55.1% in the first 6 months was down slightly versus the prior year, attributed to expenses associated with expedited freight for Clear Eyes.
Adjusted EPS Decline: Adjusted EPS of $1.98 compared to $2.13 in the prior year, reflecting the impact of lower Q1 revenues and increased air freight costs.
Increased Marketing Expenses: Advertising and marketing expenses were 14.7% of sales for the first 6 months, indicating a rise in spending as a percentage of sales compared to the prior year.
PBH FAQs
How does PBH typically perform around its earnings report dates?
Is Prestige Consumer Healthcare Inc (PBH) Q2 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PBH Earning Call Sentiment
Prestige Consumer Healthcare Inc (PBH) Q2 2025 Earnings Call Transcript
1.0x
00:00
00:00
PBH.N
-1.42%Positive
The earnings call presents a mixed picture. Basic financial performance shows slight declines and challenges with supply chain issues, but there's optimism for improvement (rated 3). Product development updates are positive, with growth in Hydralyte and potential recovery for Summer's Eve (rated 4). Market strategy is neutral due to competitive pressures and economic uncertainties (rated 3). Expenses and financial health show stable debt reduction and cash flow, but margin pressures exist (rated 3). The shareholder return plan is positive with share repurchases and debt reduction (rated 4). Overall, the sentiment is neutral, with potential for slight positive movement.
